Opinion

Video

Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.

Video content above is prompted by the following questions:

  • Do you think the results of this trial support the investigation of cretostimogene in combination with other checkpoint inhibitors?
  • Can you briefly discuss other notable trials that are investigating cretostimogene for intermediate- or high-risk NMIBC?
Related Videos
1 expert is featured in this series.
Related Content
FDA logo
December 6th 2024

FDA grants priority review to durvalumab for muscle-invasive bladder cancer

Benjamin P. Saylor
The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer
December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke
“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke
At the time of data cutoff, 71% of patients achieved a complete response following treatment.
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
November 11th 2024

Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC

Hannah Clarke
"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.
© 2024 MJH Life Sciences

All rights reserved.